Well, off to a good start I suppose?
One week into my product life-cycle portfolio, I am beating the S&P 500. I shouldn’t be too excited yet, but I can’t help but be a little excited. My strategy to invest in post-vaccine and stocks that will benefit from economic recovery seemed to pay off this week as tech went down and more value-oriented stocks went up.
And wouldn’t you know it, the company who announced today that they have seen good success metrics on their vaccine trials is in this slice of my portfolio!
Below, you can see my overall portfolio’s value as of November 10th, 2020. I’m up 7.52% overall since my portfolio’s creation compared to 5.13% for the S&P 500 during the same time period (Tracking vs. the benchmark ETF, VOO). The market has moved a lot this week, but it’s still really encouraging to be up significantly vs. the market index I’m tracking. The slice of my portfolio we will review today, Growth + High Yield, played a big factor in this outperformance by finishing the week up 10.14%.
To review the purpose of this slice of my Product Life-Cycle portfolio, I’ve taken an excerpt from my original blog post to highlight the purpose of the Growth + High Yield section of my portfolio.
Growth + High Yield (30%) – This grouping is the heart of my product portfolio. With this section of my investments, I have selected a group of companies that should overdeliver both on the dividend side and growth side of my portfolio. Theoretically, this group of stocks should be able to beat the S&P 500 on their own. These companies are close to peak performance, and I have selected a grouping that delivers both dividend and growth potential.
Portfolio Composition: What companies are included in my Growth & High Yield portfolio?
- JP Morgan Chase Co (JPM) – 10%
- Main Street Capital Corp (MAIN) – 10%
- CVS Health Corp (CVS) – 5%
- Walgreens Boots Alliance (WBA) – 5%
- Chubb Ltd (CB) – 5%
- Gladstone Investment Corp (GAIN) – 5%
- BlackRock Inc (BLK) – 5%
- Ally Financial (ALLY) – 5%
- Intel (INTC) – 5%
- Brookfield Renewable Partners (BEP) – 5%
- Horizon Bancorp Inc (HBNC) – 4%
- Navient Corp – (NAVI) – 4%
- AbbVie inc. (ABBV) – 4%
- Union Pacific Corp (UNP) – 4%
- Pfizer (PFE) – 4%
- Johnson & Johnson (JNJ) – 4%
- Invesco Ltd (IVZ) – 4%
- Novartis AG (NVS) – 4%
- Broadcom Inc (AVGO) – 4%
- Archer-Daniels Midland Co (ADM) – 4%
In the future I plan to create excel spreadsheets that allow me to share my portfolio slices and gains in a more visually appealing way, but I wanted to get my portfolio out there to the world first so you guys can follow along with what I’m up to.
This post aligns with the new-product mentality. Get your blog post out there for others to digest, review, and provide feedback. Then, as you continue to grow you make product improvements along the way. The most important part of the product journey is getting started, and what a good start we are off to this week.
Roth and Roll Finance 